Illumina Inc
Change company Symbol lookup
Select an option...
ILMN Illumina Inc
ARGX argenx SE
ENZC Enzolytics Inc
GREE Greenidge Generation Holdings Inc
MLM Martin Marietta Materials Inc
ERESW East Resources Acquisition Equity Warrant Exp 1st July 2027 *W EXP 07/01/2027
NRAC Noble Rock Acquisition Corp
DCGO DocGo Inc
VELOW Velocity Acquisition Equity Warrant Exp 24 Feb 2028 *W EXP 02/24/2028
MRC MRC Global Inc
Go

Health Care : Life Sciences Tools & Services | Large Cap Growth
Company profile

Illumina, Inc. is a provider of sequencing- and array-based solutions for genetic and genomic analysis. The Company operates through two segments: Core Illumina and GRAIL. Core Illumina products and services serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. GRAIL is a healthcare company focused on early detection of multiple cancers. Its portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed for genetic analysis. Customers use its platforms to perform whole genome, de novo, exome and ribonucleic acid (RNA) sequencing, and targeted resequencing of specific gene regions and genes. The Company's BeadArray technology produces arrays that can perform many assays simultaneously. Customers use its array-based genotyping consumables for a range of analyses, including diverse species, disease-related mutations, and genetic characteristics associated with cancer.

Closing Price
$233.56
Day's Change
16.14 (7.42%)
Bid
--
Ask
--
B/A Size
--
Day's High
235.63
Day's Low
221.81
Volume
(Above Average)
Volume:
1,796,104

10-day average volume:
1,558,879
1,796,104

Company Profile

Illumina, Inc. is a provider of sequencing- and array-based solutions for genetic and genomic analysis. The Company operates through two segments: Core Illumina and GRAIL. Core Illumina products and services serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. GRAIL is a healthcare company focused on early detection of multiple cancers. Its portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed for genetic analysis. Customers use its platforms to perform whole genome, de novo, exome and ribonucleic acid (RNA) sequencing, and targeted resequencing of specific gene regions and genes. The Company's BeadArray technology produces arrays that can perform many assays simultaneously. Customers use its array-based genotyping consumables for a range of analyses, including diverse species, disease-related mutations, and genetic characteristics associated with cancer.

Valuation Ratios

Price/Earnings (TTM)
47.91x
Price/Sales (TTM)
7.41x
Price/Book (MRQ)
3.17x
Price/Cash Flow (TTM)
34.72x
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

April 2022
Current Month
1.8M
Previous Month
1.6M
Percent of Float
1.18%
Days to Cover
2.4179 Days

Share Information

ILMN is in a share class of common stock
Float
156.5M
Shares Outstanding
157.1M
Institutions Holding Shares
1,489
87.46%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in millions.

Cash flow

Values displayed are in millions.

Company Officers

  • John Wendell Thompson
  • Francis A. deSouzaPres.
  • Sam A. SamadCFO
  • Aimee L. Hoyt
  • Alex Aravanis

Address

Insider Trading

During the most recent quarter, 7K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.